EPO Patent Publication: Recombinant Fusion Protein Targeting PD-L1 and VEGF
Summary
The European Patent Office has published patent application EP4534564A1 concerning a recombinant fusion protein that targets PD-L1 and VEGF. The patent application was filed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. and lists multiple inventors.
What changed
This document is a patent publication from the European Patent Office (EPO) detailing a recombinant fusion protein designed to target both PD-L1 and VEGF. The publication, identified as EP4534564A1, was made available on March 18, 2026, and lists ImmuneOnco Biopharmaceuticals (Shanghai) Inc. as the applicant.
This patent publication does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in drug development, particularly those working on immuno-oncology therapies. Compliance officers should note this publication as it pertains to intellectual property within the pharmaceutical sector and may impact future research and development strategies.
Source document (simplified)
RECOMBINANT FUSION PROTEIN TARGETING PD-L1 AND VEGF, AND PREPARATION AND USE THEREOF
Publication EP4534564A1 Kind: A1 Mar 18, 2026
Applicants
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Inventors
TIAN, Wenzhi, LI, Song, CHEN, Dianze, YANG, Chunmei, ZHU, Wenqi
IPC Classifications
C07K 19/00 20060101AFI20231208BHEP C07K 16/28 20060101ALI20231208BHEP C12N 15/62 20060101ALI20231208BHEP C12N 15/63 20060101ALI20231208BHEP A61K 38/17 20060101ALI20231208BHEP A61K 39/395 20060101ALI20231208BHEP A61P 1/16 20060101ALI20231208BHEP A61P 27/02 20060101ALI20231208BHEP A61P 35/00 20060101ALI20231208BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.